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CObjectives: The Work Productivity and Activity Impairment Question-
naire (WPAI) is an instrument that measures work impairment in the
setting of different diseases. One previous study validating the WPAI in
Crohn’s disease (CD) patients suggested that its reproducibility may be
unsatisfactory. This study evaluated the validity and reproducibility of
the Spain Spanish version of the WPAI questionnaire in CD patients.
Methods: In a prospective study, convergent validity was tested com-
paring WPAI with quality of life and CD activity indices. Known-groups
validity was assessed by comparing WPAI scores in CD patients with
active versus inactive disease. Reproducibility of repeated tests was
evaluated by comparing two WPAI measures obtained two to four
weeks apart in stable patients. Results: One hundred eight patients O
osp
in.
al So
doi:10.1016/j.jval.2011.02.1179ere included in the various steps of the analysis. The WPAI showed
dequate known groups validity and convergent validity. The repro-
ucibility of the test and, specifically, that of the evaluation of presen-
eeism (the impairment of productivity while working) were good.
onclusions: This study confirms the validity of WPAI for measuring
ork impairment in CD patients. In contrast to previous studies, the
est reproducibility was adequate.
eywords: Crohn’s disease, inflammatory bowel disease, quality of life,
ork productivity.
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utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The Work Productivity and Activity Impairment Questionnaire (WPAI)
is a useful instrument for measuring time off work, presenteeism (the
loss of productivity while at work), and overall work impairment in a
specified health problem [1]. Currently, therapeutic trials in Crohn’s dis-
ease (CD) use this questionnaire to assess the effect of therapy on work
capacity [2,3]. The first validation of the WPAI for CD patients was per-
ormed as a substudy of a randomized study of certolizumab [3]. In a
subsequentstudyweaimedtovalidate theSpainSpanishversionof the
questionnaire [4].Unexpectedlywefoundthatthemeasurementofpre-
enteeism was inadequate and showed low reproducibility. The aim of
ur study was to validate the questionnaire in a new group of CD pa-
ients, paying special attention to its reproducibility.
Material and methods
Participants
Disease diagnosis was based on conventional clinical, endoscopic,
radiological, and histological criteria [5]. Consecutive CD patients
* Address correspondence to: Xavier Calvet, Servei de Digestiu, H
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1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.were included in the study if they were between 18 and 65 years
old and were able to understand and answer the questionnaire.
Determinations were performed by a medical doctor with exten-
sive experience in questionnaire research (AM). All patients were
recruited prospectively from the inflammatory bowel disease outpa-
tient services of the three participating hospitals (Hospital de
Sabadell, Hospital de la Vall d’Hebró, and Hospital Clinic from Barce-
lona, Spain) from June 2006 to June 2008. Ethical Committee approval
was obtained and patients gave written informed consent.
Demographic data, clinical data, employment status, educa-
tional level, and medical treatment were recorded and all ques-
tionnaires were administered during the interview between inves-
tigator and patient.
Measures
WPAI:CD. The questionnaire is self-administered and comprises
six questions that elicit information on work impairment during
the previous seven days: 1) employment status; 2) hours missed
due to CD; 3) hours missed due to other causes; 4) hours actually
worked; 5) presenteeism or degree of reduction in productivity
while working due to CD; and 6) degree of impairment of regular
activities due to CD. Major measures of the questionnaire are: 1)
ital de Sabadell, Institut Universitari Parc Taulí, Universitat Au-
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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or percent impairment while working due to CD; 3) percent overall
work impairment due to CD; and 4) regular activities impairment.
Scores are expressed as percentages of impairment/ productivity
loss, with higher scores indicating greater impairment. The for-
mulas for calculating these items are available online [6].
The Harvey Bradshaw index [7] measures clinical activity. The
variables included are: general well-being (0–4 points), abdominal
pain (0–3 points), number of liquid stools per day, presence of an
abdominal mass (0–3 points) and presence of complications (1
point for each). The sum ranges between remission and severe
relapse of the disease.
The 9-item version of the Inflammatory Bowel Disease Quality
of Life Questionnaire [8] is an abbreviated, easy-to-perform, ver-
sion of the Inflammatory Bowel Disease Quality of life-36 item
questionnaire, which has been validated in Spain Spanish. The
score ranges from nine points (worst quality of life) to 56 points
(best quality of life).
The EuroQol-5D [9] is a short generic questionnaire of QoL that
includes five items representing five dimensions of health: mobil-
ity, self-care, usual activities, pain/discomfort, and anxiety/de-
pression. The EuroQol-5D also includes a visual analog scale. The
two EuroQol-5D measures were used for all comparisons: the in-
dex of five dimensions and the visual analog scale.
All three questionnaires—the Harvey Bradshaw index, the
9-item version of the Inflammatory Bowel Disease Quality of Life
Questionnaire and the EuroQol-5D—are self-administered and
have previously been translated and validated in Spain Spanish.
Validation of the questionnaire
The questionnaire was validated by measuring its psychometric
properties, validity, and reliability, in a group of 108 patients.
Validity was evaluated by measuring convergent validity.
Convergent validity.Convergent validity assesses the correlation
etween two instruments that measures similar concepts [10]. We
hypothesized that work productivity measured by WPAI is directly
correlated with the activity of the disease (more activity of the
disease leading to more impairment at work) and with the health-
related quality of life (better health-related quality of life will be
correlated with less impairment at work). Convergent validity of
WPAI was established by correlating the WPAI scores to the Harvey-
Bradshaw index [7], the 9-item version of the Inflammatory Bowel
isease Quality of Life Questionnaire [8], and the EuroQol-5D [9]. The
Spearman rank correlation was used.
Known-groups validity. Known-groups validity; that is, the ca-
pacity to discriminate between two populations that are expected
to differ in terms of the variable evaluated [10]. In this study,
known-groups validity was measured by comparing the WPAI be-
tween patients with active (Harvey-Bradshaw score 2) and inac-
tive CD [7] through independent Student’s t test. A P value lower
than 0.05 was considered statistically significant.
Reliability
The reliability of the WPAI was measured by test–retest reliability
or reproducibility (that measures the stability of an instrument
over time). The WPAI questionnaire was administered twice with
an interval of 2 to 4 weeks to stable patients. Patients were con-
sidered stable when the Harvey Bradshaw score had not changed
and both the investigator and the patient agreed that the patient’s
clinical condition was stable. The intraclass correlation coefficient
was calculated. Values above 0.7 were considered good.
Responsiveness
Responsiveness refers to the instrument’s ability to detect changes.
Responsiveness evaluation was not performed in our study because
patients with a change in their clinical condition are rather difficult torecruit and the previous validation study by our group already in-
cluded responsiveness with excellent results [4].
Results
One hundred eight ambulatory CD patients were included in the
study. Characteristics of the patients are shown in Table 1.
Convergent validity
Table 2 shows the WPAI correlation with the questionnaires eval-
uated. Correlations were between 0.39 and 0.77. Correlations be-
tween 0.4 and 0.7 are generally considered as moderate [11]. So,
correlation ranged from moderate to good. Quality of life mea-
sures were best correlated with presenteeism and overall work
Table 1 – Characteristics of the patients with Crohn’s
disease included in the analysis (N = 108).
Age (y, mean  SD) 34.4  9.0
Sex: n (%)
Men 52 (48%)
Women 56 (52%)
Age at diagnosis: n (%)
Under 16 y 11 (10.2%)
Between 16–40 y 86 (79.6%)
Over 40 y 11 (10.2%)
Activity of the disease: n (%)
Active disease 38 (35.2%)
Inactive disease 70 (64.8%)
Localization: n (%)
Colon 24 (22.2%)
Ileo-colic 35 (32.4%)
Ileon 47 (43.5%)
Other 2 (1.9%)
Treatment: n (%)
5-ASA 8 (7.4%)
Azatioprine 74 (68.5%)
Infliximab 2 (1.9%)
Other/combination 24 (22.2%)
Time from diagnosis: (months) (mean  SD) 99.2  74
Surgery: n (%) 36 (33.3%)
Psychiatric treatment: (%) 12 (11.1%)
Work status: (%)
Actively working 97 (89.8%)
Temporal sick leave 11 (10.2%)
Educational level: (%)
Primary 34 (31.5%)
Secondary 44 (40.7%)
University 30 (27.8%)
Basal score of the questionnaires (mean  SD)
WPAI: Work missed (%) 13.3  32
WPAI: Presenteeism (%) 27.1  33.2
WPAI: Overall work impairment (%) 16.5  21.0
WPAI: Overall regular activities impairment (%) 13.1  18.8
IBDQ-9 46.1  10.3
EuroQol 5-D 0.8  0.18
Visual analog scale 70.2  17
Harvey-Bradshaw score 2.6  2.9
IBDQ-9, 9-item version of the Inflammatory Bowel Disease Quality
of Life Questionnaire; WPAI, Work Productivity and Activity Impair-
ment Questionnaire.impairment.
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The mean WPAI-CD values for absenteeism, presenteeism, overall
work impairment, and regular activity impairment scores were
significantly lower in the 70 patients with inactive disease than in
the 38 with active disease: 4.2% 17.1% versus 29.8% 44.5% (P
0.01), 8.5%  13.2% versus 36.2%  23.8% (P  0.01), 12.3%  20.7%
ersus 54.6%  34.7% (P  0.01) and 6.5%  10.0% versus 29.6% 
4.5% (P  0.01), respectively.
Reliability/test-retest reproducibility
Seventy-six patients answered the WPAI-CD two times. The ques-
tionnaires were administered twice, with an interval of between
two and four weeks. WPAI-CD time missed, presenteeism, overall
work impairment and regular activities impairment were similar
between the first and the second WPAI: 13.9% versus 9.7%, 16.3%
versus 15.7%, 13.7% versus 14.1%, and 13.1% versus 14.5%, respec-
tively. Intraclass correlation coefficient for time missing was 0.92
(95% confidence interval [CI] 0.88–0.95). Corresponding values
were 0.86 (95% CI 0.76–0.91) for presenteeism, 0.95 (95% CI 0.92–
0.97) for overall work impairment, and 0.72 (95% CI 0.54–0.83) for
regular activities impairment.
Discussion
This study confirms the validity and reproducibility of WPAI-CD as
a tool to assess work impairment in CD patients. Specifically, the
study confirms previous results showing an adequate validity
[4,12]. In contrast with our previous results [4], this validation
shows that the measure of presenteeism was reproducible. This
finding coincides with the results of previous evaluations of the
psychometric properties of the WPAI questionnaire in both CD
and in other settings [3,12].
The reasons for the differences between our previous valida-
tion and this study are unclear. Both validations use a similar
sample size, the same recall time and the same questionnaire. The
only difference was the proportion of active versus inactive pa-
tients (35% vs. 65%) in this study, whereas in the previous study
63% of patients were active. The inclusion of a higher proportion of
patients with active CD, and, thus, with more potential for
changes in work status, may explain the changes in presenteeism
observed between the first and the second measure in the previ-
ous validation [4]. Nevertheless, both studies used the same crite-
ria and required a stable Harvey Bradshaw score plus the confir-
Table 2 – Convergent validity of the Work Productivity and
measured by the Spearman rank correlation.
IBDQ-9 Euroqol-
Work missed 0.39 0.41
Presenteeism 0.77 0.57
Overall work impairment 0.68 0.57
Regular activities impairment 0.60 0.41
IBDQ-9, 9-item version of the Inflammatory Bowel Disease Quality ofmation of stability from the patient and the interviewer forinclusion in the reproducibility analysis. A false positive test after
multiple statistical comparisons is another possible alternative to
explain the previous results.
Our study further confirms that WPAI-CD is a valid and re-
producible questionnaire for evaluating work impairment in CD
patients.
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